FISCHER MEDICAL VENTURES LIMITED
Fischer Medical Ventures Limited engages in the manufacture, distribution, leasing, and maintenance of medical equipment in India and internationally. Its product portfolio includes magnetic resonance imaging (MRI) systems; preventive health kiosks; e-health access points; software solutions; cancer, TB screening, and handheld x-ray; spincare technology; nutraceuticals from plant extracts; mental health solutions; contactless screening solutions; and CT scan systems, as well as preventive diagnostic devices and ancillary medical instruments. The company was formerly known as Fischer Chemic Limited and changed its name to Fischer Medical Ventures Limited in March 2024. Fischer Medical Ventures Limited was incorporated in 1993 and is headquartered in Chennai, India.
Valuation
Profitability
Returns
Solvency
AI Summary
Indian StockStrengths1
- Strong 5-year revenue CAGR of 129.8%
Concerns1
- Low return on equity of 0.5%
Rule-based from financial data. Not advice.
Monthly Returns
Year-to-Date ROI
Historical Volatility
Historical Performance
Revenue, profitability, and cash flow trends (βΉ Crores)
Revenue (10Y)
Operating Income (10Y)
Net Profit (10Y)
Operating Margin % (10Y)
Dividend Payout % (10Y)
Free Cash Flow (10Y)
Growth Summary
Latest fiscal year: Mar 2025
Historical Growth
Year-by-year revenue, profitability, and cash flow (βΉ Crores, last 10 years)
| Year | Revenue | Op. Income | Net Profit | CFO | FCF | ROE | Rev Growth 1Y | NP Growth 1Y |
|---|---|---|---|---|---|---|---|---|
| Mar 2025 | βΉ5.22 Cr | β | βΉ0.66 | β | β | 0.2% | -54.7% | 65.0% |
| Mar 2024 | βΉ11.53 Cr | β | βΉ0.40 | β | β | 0.5% | 6305.6% | -1100.0% |
| Mar 2023 | βΉ0.18 | β | βΉ-0.04 | β | β | 14.8% | β | -82.6% |
| Mar 2022 | βΉ0.00 | β | βΉ-0.23 | β | β | 100.0% | -100.0% | -264.3% |
| Mar 2021 | βΉ0.17 | β | βΉ0.14 | β | β | β | -5.6% | -450.0% |
| Mar 2020 | βΉ0.18 | β | βΉ-0.04 | β | β | 28.6% | -1900.0% | β |
| Mar 2019 | βΉ-0.01 | β | βΉ0.00 | β | β | 0.0% | 0.0% | β |
| Mar 2018 | βΉ-0.01 | β | βΉ0.00 | β | β | 0.0% | β | -100.0% |
| Mar 2017 | βΉ0.00 | β | βΉ-0.07 | β | β | 70.0% | β | 133.3% |
| Mar 2016 | βΉ0.00 | β | βΉ-0.03 | β | β | 75.0% | -100.0% | -200.0% |
Financial Statements
Income statement, balance sheet, and cash flow (βΉ Crores, as reported)
Consolidated Figures in USD Millions.
| Unnamed: 0 | TTM |
|---|---|
| Revenue / Net Sales | 17.19 |
| Total Expenses | 17.43 |
| EBIT / Operating Profit | -0.24 |
| OPM % | -1.40% |
| Other Income | 3.75 |
| Finance Costs | 2.56 |
| Depreciation & Amortisation | 0.29 |
| Profit Before Tax | 0.66 |
| Tax % | - |
| Net Profit / PAT | -0.46 |
| EPS (βΉ) | -0.01 |
| Dividend Payout % | - |
Peer Comparison
Healthcare sector peers, ranked by market cap
| Company | Market Cap | Revenue | P/E | P/B | EV/EBITDA | Rev G 1Y |
|---|---|---|---|---|---|---|
| FISCHER MEDICAL VENTURES LIMITEDthis co. | βΉ2.62 K Cr | βΉ5.22 Cr | 0.00 | 7.68 | 4662.31 | -54.7% |
| Sun Pharmaceutical Industries Ltd. | βΉ4.15 L Cr | βΉ23.00 K Cr | 88.70 | 17.43 | 72.30 | 13.5% |
| Divi's Laboratories Ltd. | βΉ1.71 L Cr | βΉ9.20 K Cr | 67.90 | 11.13 | 67.21 | 20.0% |
| Torrent Pharmaceuticals Ltd. | βΉ1.33 L Cr | βΉ9.68 K Cr | 62.50 | 15.76 | 45.64 | 13.5% |
| Cipla Ltd. | βΉ1.17 L Cr | βΉ19.05 K Cr | 22.50 | 3.51 | 19.33 | 14.9% |
| Apollo Hospitals Enterprises Ltd. | βΉ1.05 L Cr | βΉ8.20 K Cr | 75.00 | 11.28 | 54.44 | 12.8% |
| Max Healthcare Institute Limited | βΉ1.00 L Cr | βΉ2.66 K Cr | 144.00 | 11.76 | 96.84 | 13.8% |
| Industry Average | β | βΉ3.29 K Cr | 98.63 | 8.11 | 65.50 | 20.2% |